Prostate Cancer

Top Story

Flat Earth, anti-Darwinism, the myth of global warming and PSA testing

Flat Earth, anti-Darwinism, the myth of global warming and PSA testing
HemOnc Today, May 25, 2017
Derek Raghavan, MD, PhD

There have always been people of great resolve who have been absolutely certain of what they know, without necessarily having had to prove it.

There is not much point in producing a long list, but you will get the picture if I give just a few examples.

Single-fraction, high-dose brachytherapy may be viable for localized prostate cancer

May 24, 2017
Single-fraction 19 Gy high dose–rate brachytherapy may be a safe and effective treatment alternative for men with localized prostate cancer, according to study…
FDA News

FDA grants accelerated approval to Keytruda for solid tumors with specific biomarker

May 23, 2017
The FDA today granted accelerated approval to pembrolizumab for adults and children with unresectable or metastatic, microsatellite instability–high or mismatch…
In the Journals Plus

Rare cancers represent 20% of US cancer diagnoses

May 19, 2017
Rare malignancies accounted for about one in five cancer diagnoses in the United States from 2009 to 2013, according to an American Cancer Society report published in…
CME

Toward Precision Medicine for Advanced Melanoma Management: Making the Most of Targeted Agents

This activity is supported by an educational grant from Novartis.

The identification and utilization of melanoma specific biomarkers continues to be of importance for diagnosis and…
More »
Video

VIDEO: Effort to systematize approach to medicine has ‘taken on a life of its own’

January 20, 2016
More »
Featured
ASCO Annual Meeting

ASCO Annual Meeting

CME

Hot Topics in Metastatic Breast Cancer Management: Clinical Advances with CDK4/6 Inhibitors

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

While the mortality rates for advanced or metastatic breast cancer (MBC) have steadily decreased, in part due to…
More »
Editorial

Flat Earth, anti-Darwinism, the myth of global warming and PSA testing

HemOnc Today, May 25, 2017
Derek Raghavan, MD, PhD
There have always been people of great resolve who have been absolutely certain of what they know, without necessarily having had to prove it. There…

Single-fraction, high-dose brachytherapy may be viable for localized prostate cancer

May 24, 2017
Single-fraction 19 Gy high dose–rate brachytherapy may be a safe and effective treatment alternative for men with localized prostate cancer…

FDA News

FDA grants accelerated approval to Keytruda for solid tumors with specific biomarker

May 23, 2017
The FDA today granted accelerated approval to pembrolizumab for adults and children with unresectable or metastatic, microsatellite…

In the Journals Plus

Rare cancers represent 20% of US cancer diagnoses

May 19, 2017
Rare malignancies accounted for about one in five cancer diagnoses in the United States from 2009 to 2013, according to an American Cancer Society…

Study explores disproportionately higher mortality among black cancer survivors

May 19, 2017
Researchers from Barbara Ann Karmanos Cancer Institute and Wayne State University School of Medicine received a 5-year, $9 million grant from NCI to…

Meeting NewsPerspective

Affordable Care Act increases screening, early diagnosis of certain cancers

May 17, 2017
An uptake in cancer screening after implementation of the Affordable Care Act in 2014 has shifted the diagnosis of breast, lung and colorectal…

FDA News

FDA grants breakthrough therapy designation to entrectinib for NTRK fusion–positive solid tumors

May 15, 2017
The FDA granted breakthrough therapy designation to entrectinib for the treatment of NTRK fusion–positive locally advanced or metastatic solid…

Meeting NewsPerspective

BRCA mutations may increase risk for prostate cancer

May 15, 2017
Prostate cancer rates appeared significantly higher among men who harbored BRCA1 and BRCA2 mutations than the general public, according to results…

Meeting NewsPerspective

Active surveillance ‘reasonable’ for younger men with low-risk prostate cancer

May 12, 2017
Active surveillance for low-risk prostate cancer may be a reasonable option among carefully selected men aged younger than 60 years, according to…

FDA News

FDA grants orphan drug designation to larotrectinib for solid tumors with NTRK gene fusions

May 12, 2017
The FDA granted orphan drug designation to larotrectinib for the treatment of solid tumors with neurotrophic tyrosine receptor kinase–fusion…

More Headlines »
Advertisement
Advertisement